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T cells in response to cell-associated antigens. We found that Ly-6C hi TREML4 À monocytes can differentiate into Zbtb46 + Mo-DCs in response to granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) but that Ly-6C hi TREML4
+ monocytes were committed to differentiate into Ly-6C lo TREML4 + monocytes. Differentiation of Zbtb46 + Mo-DCs capable of efficient crosspriming required both GM-CSF and IL-4 and was accompanied by the induction of Batf3 and Irf4. However, monocytes require IRF4, but not BATF3, to differentiate into Zbtb46 + Mo-DCs capable of cross-priming CD8 + T cells. Instead, Irf4 À/À monocytes differentiate into macrophages in response to GM-CSF and IL-4. Thus, cDCs and Mo-DCs require distinct transcriptional programs of differentiation in acquiring the capacity to prime CD8 + T cells. These differences may be of consideration in the use of therapeutic DC vaccines based on Mo-DCs.
INTRODUCTION
Cross-presentation functions in initiating cytolytic CD8 + T cell responses during viral infections (Joffre et al., 2012) and is mediated by classical dendritic cells (cDCs) derived from the common dendritic cell progenitor (Naik et al., 2007; Liu et al., 2007) and by monocyte-derived dendritic cells (Mo-DCs) (Nierkens et al., 2013) . Efficient cross-presentation is carried out in vivo by a CD24 + cDC subset requiring IRF8 and BATF3 Satpathy et al., 2012b) , but the transcriptional requirements for Mo-DCs are undefined. In mice, monocytes can produce DCs under inflammatory conditions in vivo (Auffray et al., 2009; Cheong et al., 2010) or upon ex vivo treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF) (Inaba et al., 1992 (Inaba et al., , 1993 Caux et al., 1992) . Human monocytes treated ex vivo with GM-CSF and interleukin-4 (IL-4) also acquire DC characteristics (Sallusto and Lanzavecchia, 1994; Romani et al., 1994) . Mo-DCs express CD11c and major histocompatibility complex class II (MHC-II) (Leó n et al., 2004) , as well as the DCspecific transcription factors ZBTB46 and L-MYC (Satpathy et al., 2012a; KC et al., 2014) . However, monocytes differentiated with GM-CSF alone generate a heterogeneous population of CD11c + cells (Helft et al., 2015) , resembling either macrophages (GM-Macs, CD11b
+ MHC-II lo ) or DCs (GM-DCs, CD11b + MHC-
II hi
). GM-DCs cross-present soluble antigen more efficiently than GM-Macs do (Helft et al., 2015) .
Mo-DCs can promote T H 1 and CD8 + T cell responses (Leó n et al., 2007; Aldridge et al., 2009; Ji et al., 2013) but they differ from cDCs in the antigen processing pathways they use (Segura et al., 2009) and the phases of infection in which they are involved (Ballesteros-Tato et al., 2010) . Mo-DCs react distinctly from cDCs in response to adjuvant (Langlet et al., 2012) and, unlike cDCs, act independently of GM-CSF signaling in vivo during steady state and immunization . Human Mo-DCs generated ex vivo with GM-CSF and IL-4 can elicit CD8 + T cell responses against tumor antigens (Nestle et al., 1998; Hö ltl et al., 1999; Timmerman et al., 2002; Thurner et al., 1999) and subdominant neoantigens (Carreno et al., 2015) and they have been used in cancer vaccines (Palucka and Banchereau, 2013; Carreno et al., 2015) . Although CDPs have been suggested as sources of DC vaccines (Guilliams and Malissen, 2015) , the abundance and practical value of monocytes motivates understanding their cross-presentation capacity for use in future vaccine design.
How IL-4 regulates Mo-DC differentiation is still unclear. In macrophages, IL-4 signaling induces M2 polarization (El Chartouni et al., 2010) by STAT6 activation and induction of . JMJD3 functions as a demethylase of histone 3 lysine 27 (Ishii et al., 2009) and promotes M2 polarization by regulating IRF4 expression (Satoh et al., 2010) . Loss of either JMJD3 or IRF4 impairs expression of M2 macrophage genes such as Arg1, IL13, and Fizz1 (Satoh et al., 2010) . Whether similar actions of IL-4 and IRF4 occur during Mo-DC differentiation has not been examined. In CD11b + cDCs, IRF4 is required for migration (Bajañ a et al., 2012) , survival in mucosal tissues (Schlitzer et al., 2013; Persson et al., 2013) , and capacity to induce T H 17 and T H 2 responses (Gao et al., 2013; Williams et al., 2013; Schlitzer et al., 2013; Persson et al., 2013) . Human Mo-DCs induce IRF4 in response to GM-CSF and IL-4 (Lehtonen et al., 2005) , but its function there is undefined. In this study, we compared the transcriptional programs between cDCs and Mo-DCs for their ability to prime T cells in response to cell-associated antigens, finding that Mo-DCs do not require IRF8 and BATF3 like cDCs do but they instead require IRF4. et al., 2014). As control, both cDC subsets presented SIINFEKL peptide ( Figure 1C ). Mo-DCs generated with GM-CSF and IL-4 efficiently activated T cells in response to cell-associated antigen and SIINFEKL peptide, in contrast to Ly-6C + monocytes ( Figures 1A-1C ), as reported previously (Cheong et al., 2010) . Unlike Mo-DCs, sorted splenic Sirp-a + DCs cultured in GM-CSF with or without IL-4 did not cross-prime T cells to cell-associated antigen ( Figure 1D ) but they presented SIINFEKL peptide ( Figure 1E ). Thus, Mo-DCs, but not Sirp-a + cDCs, are able to cross-prime T cells to cell-associated antigens. Monocytes cultured in GM-CSF produce a heterogeneous population of MHC-II hi GM-DCs and MHC-II lo , in agreement with a recent study (Helft et al., 2015) . MHC-II hi GM-DCs expressed Zbtb46 gfp (Satpathy et al., 2012a) , but MHC-II lo GM-Macs did not (Figure 2A ), consistent with specific Zbtb46 expression in cDCs but not macrophages (Meredith et al., 2012; Satpathy et al., 2012a (Figure 2A ).
RESULTS

IL-4 Is
Both MHC-II hi and MHC-II lo cells that developed in GM-CSF alone were weak cross-primers of cell-associated antigen, but addition of IL-4 significantly enhanced their activity ( Figure 2B ) to levels similar to those of CD24 + cDCs ( Figures 1A and 1B ). All populations presented SIINFEKL peptide ( Figure 2C ). MHC-II lo ( Figure 2D ) and MHC-II hi ( Figure 2E ) Mo-DCs differentiated with GM-CSF alone or with IL-4 showed similar uptake of apoptotic cells. Thus, IL-4 signaling during GM-CSF-induced monocyte differentiation induces Zbtb46 expression in MHC-II lo cells and increases cross-priming in both MHC-II hi and MHC-II lo cell populations.
Expression of TREML4 and NUR77 Identifies Monocytes Lacking Mo-DC Potential TREML4, a member of the triggering receptor expressed on the myeloid cells family (Ford and McVicar, 2009) , is induced during heme-mediated differentiation of macrophages from monocytes and bone marrow (BM) progenitors (Haldar et al., 2014) . TREML4 is expressed on CD24 + cDCs, monocytes (Hemmi et al., 2012) , and macrophages, where it regulates TLR7 signaling amplification (Ramirez-Ortiz et al., 2015) . Ly-6C hi monocytes were heterogeneous for TREML4 expression, but Ly-6C lo monocytes were uniformly TREML4 positive ( Figure 3A Hanna et al., 2011) . Our analysis of Nr4a1-GFP reporter mice (Moran et al., 2011) shows that TREML4 expression increased along with Nr4a1 ( Figure 3D ). Figure 3D ). Then, we tested the DC potential of monocytes expressing different levels of Nr4a1 ( Figure 3E ). Ly-6C + Nr4a1-GFP À monocytes differentiated into Mo-DCs in response to GM-CSF and IL-4 ( Figure 3E ). In contrast, Ly-6C + Nr4a1-GFP + monocytes and Ly-6C lo Nr4a1-GFP + monocytes were unable to differentiate into CD11c + MHC-II + Mo-DCs ( Figure 3E ). Nr4a1-deficient monocytes could not develop into Ly-6C lo monocytes, as reported (Moran et al., 2011) , but could develop into Mo-DCs ( Figure 3F ). Unsupervised analysis using SPADE (Qiu et al., 2011) Figure 4A ). Specifically, Batf3 was induced by GM-CSF and IL-4 by 10-fold and 4-fold relative to monocytes and Mo-DCs cultured with GM-CSF alone, respectively. In addition, Irf4 was induced more than 25-fold relative to monocytes and 2-fold relative to Mo-DCs cultured with GM-CSF ( Figures 4A and 4B ), as reported in human Mo-DCs (Lehtonen et al., 2005) . Two other factors, Nr4a3 (DeYoung et al., 2003) and Vdr (Yoshizawa et al., 1997; Li et al., 1997) , were induced, but these have not been associated with antigen presentation. In contrast, Batf3 is required for the development of cDCs capable of cross-presentation (Hildner et al., 2008; Torti et al., 2011) , and Irf4 was shown to be required for MHC-II expression in GM-DCs (Vander Lugt et al., 2014) . Mo-DCs induced Batf3, but not Batf or Batf2, to levels equivalent to those of both splenic CD24 + and Sirp-a + cDCs ( Figure 4C ). Likewise, Mo-DCs expressed Irf4 to levels similar to those of Sirp-a + cDCs ( Figure 4C ).
Also, IL-4 increased IRF4 expression in Mo-DCs ( Figure 4D ). In summary, IL-4 induced both BATF3 and IRF4 during Mo-DC differentiation.
Cross-Priming by Mo-DCs Is Independent of BATF3
To examine Mo-DC differentiation and function, we used monocytes from Batf, Batf2, and Batf3 triple-knockout mice (Batf-TKO), since Batf and Batf2 can compensate for Batf3 in CD24 + cDC development (Tussiwand et al., 2012) . Mo-DCs developed normally from Batf-TKO monocytes ( Figure 5A ), with normal expression of IRF4 and IRF8 ( Figure 5B ). As reported (Tussiwand et al., 2012) , Batf-TKO lacked splenic CD24 + cDCs but retained Sirp-a + cDCs ( Figure 5A ). We found no difference in cross-priming between wild-type (WT) and Batf-TKO Mo-DCs over a range of antigen concentrations or in presentation of SIINFEKL peptide ( Figures 5C and 5D ). Splenic Batf-TKO Sirp-a + DCs did not cross-prime but could present SIINFEKL peptide (Figures 5E and 5F). Thus, development and cross-priming of Mo-DCs was independent of BATF3. Figures 6C and 6D ). The uptake of apoptotic cells was similar between WT and Irf4 À/À Mo-DCs ( Figure 6E ). Mo-DCs lacking IRF4 did not express MHC-II, as reported previously (Vander Lugt et al., 2014) , but expressed normal MHC class I (MHC-I) levels ( Figure 6F ). However, they were unable to induce OT-I proliferation with SIINFEKL peptide ( Figure 6G ). Unlike WT Mo-DCs, Irf4 À/À monocytes failed to induce
IRF4 Is
Zbtb46-GFP and, instead, acquired expression of F4/80 following treatment with GM-CSF and IL-4 ( Figure 7A ). IRF4 was not required for Zbtb46 expression in CD24 + or Sirp-a + splenic cDCs ( Figure 7A ). By contrast, Zbtb46-deficient Mo-DCs expressed normal levels of MHC-II and IRF4 ( Figure 7B ). Consistent with the lack of MHC-II and Zbtb46 expression, the normal DC morphology of Mo-DCs was not seen in Irf4 À/À Mo-DCs, which, instead, had the appearance of macrophages ( Figure 7C ), suggesting that IRF4 may be required for the induction of a broader DC transcriptional program in Mo-DCs beyond MHC-II gene expression.
To determine the identity of cells originating from IRF4-deficient monocytes cultured with GM-CSF and IL-4, we performed microarray analysis of WT and Irf4 À/À Mo-DCs ( Figures 7D and   7E ). Consistent with the macrophage identity observed by flow cytometry and microscopy, Irf4 À/À monocytes cultured in GM-CSF and IL-4 induced high expression of macrophage-specific genes such as Mertk, Tlr4, and Tlr7 and, unlike WT Mo-DCs, failed to induce DC-associated genes such as Figure S1 .
Kmo, Traf1, and Slamf7 ) ( Figure 7D ). Since IRF4 has been previously implicated in the development of splenic Sirp-a + cDCs (Suzuki et al., 2004) , we asked whether IRF4 regulated a similar genetic program in both Mo-DCs and splenic Sirp-a + cDCs. Comparison of the microarrays of WT and Irf4 À/À Mo-DCs showed 747 genes to be differentially expressed by at least 3-fold between these two populations ( Figure 7E ). However, only 49 of those targets were also at least 3-fold different between WT and Irf4 À/À Sirp-a + cDCs (Figure 7E 
DISCUSSION
Vaccines based on Mo-DCs can enhance immune responses against human melanoma (Carreno et al., 2015) . Mo-DCs have been generated either in culture of GM-CSF alone or with IL-4 (Linette and Carreno, 2013 (Hanna et al., 2011) but not into Mo-DCs ( Figure 3F ). We find that Ly-6C hi monocytes that express NUR77 or TREML4 lack Mo-DC potential. In CD8 + T cells, NUR77 may inhibit IRF4 expression (Nowyhed et al., 2015) , suggesting that it may act similarly in Ly-6C hi TREML4 + monocytes to repress IRF4 and, thus, Mo-DC development. The biochemical basis for cross-presentation by different cells remains incompletely understood. Several proteins implicated in cross-presentation have been analyzed only in cells generated from BM cells treated with GM-CSF alone (Joffre et al., 2012; Segura and Amigorena, 2015) . In this setting, NOX2 (Savina et al., 2006 (Savina et al., , 2009 , Rac2 (Savina et al., 2009 ) and VAMP8 (Matheoud et al., 2013) were shown to regulate acidification of phagosomes in GM-DCs, suggesting that they act to preserving antigens from complete degradation. While NOX2 and RAC2 also regulate phagosomal acidification in CD8 + cDCs (Savina et al., 2009) , only NOX2, but not RAC2, deficiency reduced CD8 + cDC cross-presentation of soluble antigen. RAB11A (Nair-Gupta et al., 2014), RAB3B (Zou et al., 2009) , and SEC22B (Cebrian et al., 2011) , which regulate vesicular trafficking, were shown to promote cross-presentation but were studied using BM cultures treated with GM-CSF or in the DC2.4 cell line. In our studies, Mo-DCs generated with GM-CSF alone were relatively inefficient in the cross-priming of cell-associated antigen, compared with CD8 + cDCs and Mo-DCs generated with both GM-CSF and IL-4 ( Figure 2B ).
Other known proteins such as ERAP1 (Firat et al., 2007) and IRAP (Segura et al., 2009; Saveanu et al., 2009 ) may be also be involved in cross-presentation. ERAP1 was required in vivo but not in GM-CSF BM-derived cells (Firat et al., 2007) , while IRAP was required for both in vivo and in vitro crosspriming of CD8 + T cells to cell-associated antigen (Saveanu et al., 2009) . IRAP was required for cross-presentation of soluble antigen only in inflammatory Mo-DCs generated in vivo and not in CD24 + DCs (Segura et al., 2009) . Alternately, unknown proteins may remain unidentified that differentially act in crosspresentation.
EXPERIMENTAL PROCEDURES Mice
Zbtb46 gfp/+ mice (Satpathy et al., 2012a) were backcrossed to C57BL/6J for at least eight generations. Batf
, and Irf4 À/À mice have been described previously (Tussiwand et al., 2012; Grajales-Reyes et al., 2015) . The following mice were purchased from Jackson Laboratory: Nr4a1 À/À (B6;129S2-Nr4a1 (legend continued on next page) following were purchased from eBioscience: CD4 (GK1.5); CD8a (53-6.7); CD11b (M1/70); CD45.1 (A20); CD44 (IM7); CD117 (2B8); CD115 (AFS98); CD11c (N418); CD24 (M1/69); CD172a (P84); Ly-6C (HK1.4); Ly-6A/E (D7); Ly-6G (IA8); Siglec-H (eBio440C); Ter-119 (Ter-119); CD105 (MJ7/18); Irf8 (V3GYWCH); CD45R (RA3-6B2); NK1.1 (PK136); Irf4 (3E4); and 7-AAD viability staining solution. The following were purchased from Tonbo Biosciences: CD45.1 (A20); and CD11c (N418). The following were purchased from BioLegend: CD8a (53-6.7); CD45.2 (104); CD115 (ASF98); Ly-6G (IA8); TCR Va2 (B20.1); and TREML4 (16E5). The following were purchased from ThermoFisher Scientific: TCR Va2 (B20.1) and the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit. Carboxyfluorescein succinimidyl ester (CFSE) was purchased from Sigma. Anti-biotin and anti-B220 microbeads were purchased from Miltenyi Biotec. Cells were fixed and permeabilized for intracellular staining of IRF4 and IRF8 using the FoxP3/Transcription Buffer Set (eBioscience). Cells were sorted on a BD FACSAria Fusion flow cytometer (BD) and with FlowJo software (Tree Star).
Isolation and Culture of BM Cells and Splenic DCs
Femurs, pelvises, and tibias were crushed using a mortar and pestle in MACS buffer, filtered through a 70-mm strainer, purified on Histopaque-119 gradient, and depleted of Ly-6G-and B220-expressing cells with biotinylated anti-Ly-6G and B220 antibodies and anti-biotin microbeads (Miltenyi Biotec 
Microscopy
Cytospins of sorted Mo-DCs generated from GM-CSF and IL-4 culture of Ly-6C + TREML4 -monocytes were stained with Wright-Giemsa stain using a Hema 3 kit (Fisher Scientific). Images were acquired at room temperature with an Axioskop microscope (objective: 1003, 1.25, oil) using an Axiocam ICc3 camera (Zeiss).
Gene Expression Microarray Analysis
Total RNA was extracted from purified splenic cDCs, Mo-DCs, and monocytes from BM and peripheral blood using the RNAqueous-Micro Kit (Ambion). RNA was amplified using the Ovation Pico WTA Sytem (NuGEN) and hybridized to GeneChip Mouse Gene 1.0 ST microarrays (Affymetrix). Data were processed using robust multiarray average summarization and quartile normalization using ArrayStar software, version 5 (DNASTAR). Expression values for cell lineages were averaged from biological duplicates, except for WT CD24 + cDCs and peripheral blood monocyte subsets, which were from one biological sample.
Antigen Presentation Assays
Splenic OT-I cells were sorted as B220
+ to > 95% purity, labeled with CFSE, and plated at a density of 12.5 3 10 5 cells/mL. Splenocytes from MHC-I TKO mice were processed as described earlier. OVA loading of MHC-I TKO splenocytes has been described previously (Carbone and Bevan, 1990) . Splenocytes (2.5 3 10 7 /mL) were incubated in hypertonic medium (RPMI 1640, 0.5 M sucrose, 10% w/v polyethylyne glycol, 10 mM HEPES [pH 7.2]) with 5 mg OVA (Worthington) for 10 min at 37 C. Cells were diluted 10-fold with hypotonic media (60% fetal bovine 
Statistical Analysis
Statistical analyses were performed using a two-way ANOVA with Sidak's multiple comparison test unless otherwise specified. All statistical analyses were performed using Prism (GraphPad Software).
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO: GSE75015. (D) MA plot of the expression ratio of DC-and macrophage (MF)-specific genes from Gautier et al., 2012) 
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